the-regulatory

Trump pushes drugmakers for lower prices, more U.S. production

WASHINGTON/LOS ANGELES (Reuters) – U.S. President Donald Trump in a meeting on Tuesday with pharmaceutical executives called on them to manufacture more of their drugs in the United States and cut prices, while vowing to speed approval …

The rest is here:
Trump pushes drugmakers for lower prices, more U.S. production

the-regulatory

Cigna says Anthem deal could close in 2017; Anthem sticks to 2016

Health insurer Cigna Corp , which announced plans to be bought by larger Anthem Inc 10 months ago, on Friday said the deal may close in 2017 rather than 2016 due to the complexity of the regulatory process, according to a filing with the Securities and Exchange Commission. The U.S. Department of Justice is currently reviewing the Cigna-Anthem deal, which would create the …

View original post here: 
Cigna says Anthem deal could close in 2017; Anthem sticks to 2016

the-regulatory

Exclusive: Pfizer negotiating 2-3 percent Allergan break-up fee – sources

A break-up fee of that amount, to be paid by Pfizer if it were to walk away from the Allergan deal, would show confidence that the regulatory risk to the merger does not pose an existential threat, despite the U.S. Treasury planning this week to tighten the rules on corporate tax inversions, a key aspect of their plan. The break-up fee…

More here: 
Exclusive: Pfizer negotiating 2-3 percent Allergan break-up fee – sources